Accessibility Menu
Biora Therapeutics logo

Biora Therapeutics(OTC) BIORQ

Market Cap$500.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-100%
1 Year-91%
1 Month+0%
$0.00
+0.00%
+0.00Today
Biora Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-07
Biora Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-31
1 month+0%USD 0.002026-07-08
3 month-50%USD 0.002026-05-08
Year to date+9,900%USD 0.002025-12-31
1 year-90.91%USD 0.002025-08-07
3 year-100%USD 36.902023-08-08
5 year-100%USD 485.002021-08-06
Since inception-100%USD 3,280.002020-06-19

Biora Therapeutics Financials at a Glance

Market Cap

$500.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.76M

Net Income (TTM)

-$31.54M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

2.99 (High)

Price

$0.00

Volume

141

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

Aug 11, 2026

BIORQ News

GettyImages-1264101698

Why Shares of Progenity Are Down More Than 11% on Wednesday

James HalleyDec 1, 2021
Progenia

Why Progenity Stock Is Up More Than 34% Tuesday

James HalleyNov 16, 2021
GettyImages-487041721

Why Progenity Stock Was Up More Than 24% Friday

James HalleyOct 22, 2021
GettyImages-672153331

Why Progenity Stock Is Soaring on Tuesday

James HalleyOct 12, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biora Therapeutics

Biora Therapeutics, Inc. is a biotechnology company focused on developing innovative oral biotherapeutics. The company aims to enhance treatment efficacy for gastrointestinal diseases through advanced therapeutic delivery systems.

Products and Services
  • Targeted Therapeutics Program using ingestible smart capsules
  • Systemic Therapeutics Program for non-invasive biotherapeutic delivery
  • Diagnostic devices for evaluating gastrointestinal conditions
Growth Outlook
  • Recent quarterly revenue increased to $32,000 from $318,000
  • Research and development expenses indicate ongoing commitment to innovation
  • Strategic focus on therapeutic product pipeline following rebranding in 2022
Financial Highlights
  • Trailing twelve months revenue of $1.1 million
  • Net income for Q3 2024 reported at -$18.4 million
  • Cash and cash equivalents at $3.2 million as of September 30, 2024
Biora Therapeutics, Inc. operates in a dynamic biotechnology sector, emphasizing the development of oral biotherapeutics. The company's innovative approach includes targeted and systemic therapeutic programs, which aim to improve treatment outcomes for patients with gastrointestinal diseases. The recent rebranding reflects a strategic pivot towards enhancing its therapeutic product pipeline, which may attract investor interest. The growth outlook appears promising, with a focus on research and development, despite recent fluctuations in revenue. The company reported a revenue increase in the latest quarter, indicating potential for future growth. However, the financial landscape shows challenges, with a significant net loss reported in Q3 2024. The cash position remains critical, with $3.2 million available to support ongoing operations and development efforts. Investors may find Biora Therapeutics, Inc. an intriguing opportunity within the biotechnology space, particularly given its innovative product offerings and strategic focus on gastrointestinal health.
AI Generated • Jul 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

58

CEO

Adi Mohanty, MBA

Website

www.bioratherapeutics.com

Headquarters

San Diego, CA 92122, US

BIORQ Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-1678575.00%

Net Income Margin

-3102875.00%

Return on Equity

121.86%

Return on Capital

N/A

Return on Assets

-397.61%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$500.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.52M

Volume

141

Avg. Volume

1.25K

Financials (TTM)

Gross Profit

$665.00K

Operating Income

-$60.87M

EBITDA

-$24.06M

Operating Cash Flow

-$5.37M

Capital Expenditure

-$280.00K

Free Cash Flow

-$5.50M

Cash & ST Invst.

$3.20M

Total Debt

$39.65M

Biora Therapeutics Performance Analysis

Biora Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 1,247,000N/A
20222022-12-31USD 305,000-75.5%
20232023-12-31USD 4,000-98.7%
Biora Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-31N/A
Q12024-03-31-37.8%
Q22024-06-30-41.3%
Q32024-09-30-89.9%
Biora Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -643.27N/A
20222022-12-31USD -49.98-92.2%
20232023-12-31USD -78.6957.5%
Biora Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-12-3187.3%
Q12024-03-3177.4%
Q22024-06-30-185.7%
Q32024-09-30-1160.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$32.00K

N/A

Gross Profit

$32.00K

+125.6%

Gross Margin

100.00%

N/A

Market Cap

$500.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$8.62

N/A

Employees

58

N/A

Net Income

-$18.40M

+74.9%

EBITDA

-$16.23M

+77.1%

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$3.20M

-74.6%

Total Debt

$39.65M

-51.9%

Accounts Receivable

$868.00K

+6.1%

Inventory

$0.00

N/A

Long Term Debt

$14.68M

-82.0%

Short Term Debt

$24.97M

+2495.1%

Return on Assets

-3.98%

N/A

Return on Invested Capital

2.11%

N/A

Free Cash Flow

$31.95M

+389.5%

Operating Cash Flow

$31.82M

+388.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MRZMMarizyme, Inc.
$0.00+0.00%
EDXCEndexx Corporation
$0.00+0.00%
HALBHalberd Corporation
$0.00-12.50%
BPTHBio-Path Holdings, Inc.
$0.04+5.26%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$133.11+0.16%
TTDThe Trade Desk
$13.80-0.22%
NVDANvidia
$223.96+0.02%
TLTiShares Trust - iShares 20+ Year Treasury Bond ETF
$82.76+0.00%

Questions About BIORQ

What is the current price of Biora Therapeutics?

Biora Therapeutics is trading at $0.00 per share.

What is the 52-week range for Biora Therapeutics?

Over the past 52 weeks, Biora Therapeutics has traded between $0.00 and $0.01.

How much debt does Biora Therapeutics have?

As of the most recent reporting period, Biora Therapeutics reported total debt of $39.65M.

How much cash does Biora Therapeutics have on hand?

Biora Therapeutics reported $3.20M in cash and cash equivalents in its most recent financial results.

What is Biora Therapeutics’s dividend yield?

Biora Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services